A detailed history of Allworth Financial LP transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 397 shares of VERV stock, worth $2,147. This represents 0.0% of its overall portfolio holdings.

Number of Shares
397
Previous 170 133.53%
Holding current value
$2,147
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$4.4 - $7.86 $998 - $1,784
227 Added 133.53%
397 $1,000
Q2 2024

Jul 23, 2024

BUY
$4.76 - $12.79 $809 - $2,174
170 New
170 $0
Q3 2023

Oct 31, 2023

SELL
$11.42 - $20.82 $1,107 - $2,019
-97 Reduced 98.98%
1 $0
Q2 2023

Jul 18, 2023

BUY
$13.34 - $19.9 $146 - $218
11 Added 12.64%
98 $1,000
Q1 2023

Apr 18, 2023

BUY
$14.3 - $24.01 $1,244 - $2,088
87 New
87 $1,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $324M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.